KLIFOVET AG

Their core work

KLIFOVET AG is a Munich-based veterinary clinical research SME specializing in farm animal health, particularly in reducing antimicrobial use in livestock production. They design and conduct farm-level trials to evaluate alternatives to antibiotics — including feed additives, gut stabilizers, immunostimulants, and bacteriophages — for pigs and dairy cattle. Their work bridges the gap between laboratory research and practical on-farm validation, making them a valuable partner for projects that need real-world efficacy data in livestock settings.

What they specialise in

How they've shifted over time

KLIFOVET AG's earliest H2020 involvement (2018) focused on emergency preparedness for emerging livestock diseases like African Swine Fever and Lumpy Skin Disease through the DEFEND project. From 2019 onward, their focus shifted decisively toward reducing antibiotic use in farming — first through non-medicated feed additives for dairy cows (RumenShield Dairy), then through a broader portfolio of antimicrobial alternatives for pigs (AVANT). This evolution mirrors the EU's growing regulatory push to eliminate routine antibiotic use in agriculture.

KLIFOVET AG is moving firmly into the antibiotic-free livestock production space, positioning them for growing demand as EU regulations tighten restrictions on veterinary antimicrobials.

How they like to work

KLIFOVET AG operates exclusively as a consortium participant, never as coordinator, which is consistent with their role as a specialized service provider contributing farm trial expertise to larger research efforts. With 50 unique partners across 27 countries in just 3 projects, they work in large, multi-national consortia — typical of major EU Innovation and Research Actions. This suggests they are comfortable integrating into complex project structures and delivering defined work packages rather than leading overall project direction.

Despite only three projects, KLIFOVET AG has built a remarkably broad network of 50 partners across 27 countries, reflecting the large-scale consortia typical of EU agricultural research. Their reach spans nearly all EU member states and likely includes veterinary institutes, universities, and farming organizations across Europe.

What sets them apart

KLIFOVET AG occupies a specific niche as a private SME that conducts veterinary clinical trials on farms — a capability that academic partners often lack. Their name ("Klifovet" likely from "Klinische Forschung Veterinär") signals deep roots in veterinary clinical research. For any consortium developing new feed additives, vaccines, or antimicrobial alternatives for livestock, they offer the practical trial infrastructure and regulatory know-how to move from lab results to field-validated evidence.

Highlights from their portfolio

• AVANT
  Directly addresses the EU's top agricultural policy priority — reducing antibiotic use — with a comprehensive portfolio approach covering gut stabilizers, immunostimulants, and bacteriophages for pigs.
• RumenShield Dairy
  Their largest funded project (EUR 477,838) combining two high-value goals: improving dairy productivity while reducing methane greenhouse gas emissions through non-medicated feed additives.
• DEFEND
  Addresses African Swine Fever — one of Europe's most economically devastating animal diseases — though their minimal funding (EUR 3,125) suggests a very targeted advisory or coordination support role.